Sonoma Pharmaceuticals, Inc. (SNOA)

Over the past six months, Sonoma Pharmaceuticals' stock price has declined by 46.98%. Key events include the FDA registration of its manufacturing facility, the launch of a new HOCl wound cleanser for Medline Industries, and the release of positive financial results for the second and third fiscal quarters of 2026. Reliefacyn received the National Rosacea Society Seal of Acceptance. The company launched a new dermatology product line under Person & Covey's Aquanil Brand and its Advanced Burn Relief Hydrogel in CVS and Walmart stores. Sonoma entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC.

Information regarding explicit demand seasonality for Sonoma Pharmaceuticals, Inc.'s products and services is limited. Revenues from regions like Asia and the Rest of the World tend to fluctuate on a quarterly basis due to customer purchasing patterns rather than inherent seasonal variations.

Sonoma Pharmaceuticals, Inc. specializes in developing and producing stabilized hypochlorous acid (HOCl) products using its patented Microcyn® technology. The company operates in the medicinal and botanical manufacturing and healthcare products space, focusing on specialty and generic pharmaceuticals. Sonoma's product portfolio addresses wound care, eye care, oral and nasal care, dermatological conditions, podiatry, and animal health care, featuring products like Lumacyn, Regenacyn, and MicrocynAH.

Sonoma Pharmaceuticals has a global presence, selling products in over 55 countries through direct sales and partnerships. The company's principal office is in Boulder, Colorado, with manufacturing in Guadalajara, Mexico, and European marketing and sales in Roermond, Netherlands. Revenue comes from the United States, Europe, Latin America, Asia, and other regions.

Sonoma Pharmaceuticals has strengthened its brand reputation through successful transition to the European Union Medical Device Regulation (MDR) and FDA registration as a medical device establishment. The company registered its manufacturing facility and listed a Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Rosacea Society Seal of Acceptance.

Sonoma Pharmaceuticals has a mixed ownership structure. Institutional investors own approximately 4.17% to 7.13% of the stock, while insiders hold about 29.35%. Public companies and individual investors own the largest portion, approximately 63.52% of the stock. Major institutional owners include DRW Securities, LLC, and Vanguard Group Inc. Bruce Thornton owns the most shares.